ArticleMolecular & cellular oncology2026
Integrative multi-omics profiling identifies a lactylation-associated, metabolically active, and immunosuppressive subtype of colon adenocarcinoma.
Article in Molecular & cellular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Histone lactylation, a lactate-derived post-translational modification, bridges metabolic activity and gene regulation. However, its molecular mechanisms and clinical significance in colon adenocarcinoma (COAD) remain poorly characterized. Methods: We conducted multi-omics analyses on TCGA and GTEx datasets, characterizing lactylation-associated genes via differential expression, enrichment, mutation profiling, and immune deconvolution. Subsequent prognostic modeling, transcriptional network construction, and drug sensitivity predictions assessed their biological and clinical relevance. Results: We identified 133 lactylation-associated genes and constructed an eight-gene prognostic signature ( Conclusions: Lactylation-associated transcriptional programs delineate a metabolically active, immunosuppressed COAD subtype characterized by adverse prognoses and therapeutic resistance. This lactylation-based score serves as a clinically relevant biomarker and a promising target for combined metabolic-epigenetic and immunotherapeutic interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.